SOV-2012-F1

SOV-2012-F1 is a proprietary oral formulation of testosterone undecanoate developed for testosterone replacement therapy (TRT) in men with hypogonadism. The drug uniquely utilizes phytosterol esters to enhance absorption through the lymphatic system, aiming to provide higher and more stable levels of free testosterone compared to existing therapies. This innovative approach is designed to improve patient compliance by offering convenient oral dosing, reduce adverse events associated with poor therapeutic control, and deliver consistent symptom relief. Clinical data indicate that SOV-2012-F1 outperforms leading topical gels in key quality-of-life measures such as emotional well-being, energy levels, sexual desire, erectile function, and prostate symptom scores[1][3][4]. It is currently being evaluated in late-stage clinical trials.

Brand names

Kyzatrex

Other names

oral testosterone undecanoateTU